The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients

Muireann T. Kelleher, Gilbert Fruhwirth, Gargi Patel, Enyinnaya Ofo, Frederic Festy, Paul R. Barber, Simon M. Ameer-Beg, Borivoj Vojnovic, Cheryl Gillett, Anthony Coolen, G. Kéri, Paul A. Ellis, Tony Ng

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Genomics and proteomics will improve outcome prediction in cancer and have great potential to help in the discovery of unknown mechanisms of metastasis, ripe for therapeutic exploitation. Current methods of prognosis estimation rely on clinical data, anatomical staging and histopathological features. It is hoped that translational genomic and proteomic research will discriminate more accurately than is possible at present between patients with a good prognosis and those who carry a high risk of recurrence. Rational treatments, targeted to the specific molecular pathways of an individual's high-risk tumor, are at the core of tailored therapy. The aim of targeted oncology is to select the right patient for the right drug at precisely the right point in their cancer journey. Optical proteomics uses advanced optical imaging technologies to quantify the activity states of and associations between signaling proteins by measuring energy transfer between fluorophores attached to specific proteins. Förster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM) assays are suitable for use in cell line models of cancer, fresh human tissues and formalin-fixed paraffin-embedded tissue (FFPE). In animal models, dynamic deep tissue FLIM/FRET imaging of cancer cells in vivo is now also feasible. Analysis of protein expression and post-translational modifications such as phosphorylation and ubiquitination can be performed in cell lines and are remarkably efficiently in cancer tissue samples using tissue microarrays (TMAs). FRET assays can be performed to quantify protein-protein interactions within FFPE tissue, far beyond the spatial resolution conventionally associated with light or confocal laser microscopy. Multivariate optical parameters can be correlated with disease relapse for individual patients. FRET-FLIM assays allow rapid screening of target modifiers using high content drug screens. Specific protein-protein interactions conferring a poor prognosis identified by high content tissue screening will be perturbed with targeted therapeutics. Future targeted drugs will be identified using high content/throughput drug screens that are based on multivariate proteomic assays. Response to therapy at a molecular level can be monitored using these assays while the patient receives treatment: utilizing re-biopsy tumor tissue samples in the neoadjuvant setting or by examining surrogate tissues. These technologies will prove to be both prognostic of risk for individuals when applied to tumor tissue at first diagnosis and predictive of response to specifically selected targeted anticancer drugs. Advanced optical assays have great potential to be translated into real-life benefit for cancer patients.

Original languageEnglish
Pages (from-to)235-252
Number of pages18
JournalTargeted Oncology
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Proteomics
Technology
Energy Transfer
Neoplasms
Optical Imaging
Therapeutics
Microscopy
Proteins
Pharmaceutical Preparations
Confocal Microscopy
Paraffin
Formaldehyde
Recurrence
Cell Line
Ubiquitination
Patient Rights
Post Translational Protein Processing
Genomics
Animal Models
Phosphorylation

Keywords

  • Biomarker
  • Breast cancer
  • FLIM
  • FRET
  • Imaging
  • Molecular diagnostics
  • Optical proteomics
  • Personalized medicine
  • Tissue microarray

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. / Kelleher, Muireann T.; Fruhwirth, Gilbert; Patel, Gargi; Ofo, Enyinnaya; Festy, Frederic; Barber, Paul R.; Ameer-Beg, Simon M.; Vojnovic, Borivoj; Gillett, Cheryl; Coolen, Anthony; Kéri, G.; Ellis, Paul A.; Ng, Tony.

In: Targeted Oncology, Vol. 4, No. 3, 09.2009, p. 235-252.

Research output: Contribution to journalArticle

Kelleher, MT, Fruhwirth, G, Patel, G, Ofo, E, Festy, F, Barber, PR, Ameer-Beg, SM, Vojnovic, B, Gillett, C, Coolen, A, Kéri, G, Ellis, PA & Ng, T 2009, 'The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients', Targeted Oncology, vol. 4, no. 3, pp. 235-252. https://doi.org/10.1007/s11523-009-0116-y
Kelleher, Muireann T. ; Fruhwirth, Gilbert ; Patel, Gargi ; Ofo, Enyinnaya ; Festy, Frederic ; Barber, Paul R. ; Ameer-Beg, Simon M. ; Vojnovic, Borivoj ; Gillett, Cheryl ; Coolen, Anthony ; Kéri, G. ; Ellis, Paul A. ; Ng, Tony. / The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. In: Targeted Oncology. 2009 ; Vol. 4, No. 3. pp. 235-252.
@article{e6638b02be2d4c6b85b25de91844b226,
title = "The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients",
abstract = "Genomics and proteomics will improve outcome prediction in cancer and have great potential to help in the discovery of unknown mechanisms of metastasis, ripe for therapeutic exploitation. Current methods of prognosis estimation rely on clinical data, anatomical staging and histopathological features. It is hoped that translational genomic and proteomic research will discriminate more accurately than is possible at present between patients with a good prognosis and those who carry a high risk of recurrence. Rational treatments, targeted to the specific molecular pathways of an individual's high-risk tumor, are at the core of tailored therapy. The aim of targeted oncology is to select the right patient for the right drug at precisely the right point in their cancer journey. Optical proteomics uses advanced optical imaging technologies to quantify the activity states of and associations between signaling proteins by measuring energy transfer between fluorophores attached to specific proteins. F{\"o}rster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM) assays are suitable for use in cell line models of cancer, fresh human tissues and formalin-fixed paraffin-embedded tissue (FFPE). In animal models, dynamic deep tissue FLIM/FRET imaging of cancer cells in vivo is now also feasible. Analysis of protein expression and post-translational modifications such as phosphorylation and ubiquitination can be performed in cell lines and are remarkably efficiently in cancer tissue samples using tissue microarrays (TMAs). FRET assays can be performed to quantify protein-protein interactions within FFPE tissue, far beyond the spatial resolution conventionally associated with light or confocal laser microscopy. Multivariate optical parameters can be correlated with disease relapse for individual patients. FRET-FLIM assays allow rapid screening of target modifiers using high content drug screens. Specific protein-protein interactions conferring a poor prognosis identified by high content tissue screening will be perturbed with targeted therapeutics. Future targeted drugs will be identified using high content/throughput drug screens that are based on multivariate proteomic assays. Response to therapy at a molecular level can be monitored using these assays while the patient receives treatment: utilizing re-biopsy tumor tissue samples in the neoadjuvant setting or by examining surrogate tissues. These technologies will prove to be both prognostic of risk for individuals when applied to tumor tissue at first diagnosis and predictive of response to specifically selected targeted anticancer drugs. Advanced optical assays have great potential to be translated into real-life benefit for cancer patients.",
keywords = "Biomarker, Breast cancer, FLIM, FRET, Imaging, Molecular diagnostics, Optical proteomics, Personalized medicine, Tissue microarray",
author = "Kelleher, {Muireann T.} and Gilbert Fruhwirth and Gargi Patel and Enyinnaya Ofo and Frederic Festy and Barber, {Paul R.} and Ameer-Beg, {Simon M.} and Borivoj Vojnovic and Cheryl Gillett and Anthony Coolen and G. K{\'e}ri and Ellis, {Paul A.} and Tony Ng",
year = "2009",
month = "9",
doi = "10.1007/s11523-009-0116-y",
language = "English",
volume = "4",
pages = "235--252",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients

AU - Kelleher, Muireann T.

AU - Fruhwirth, Gilbert

AU - Patel, Gargi

AU - Ofo, Enyinnaya

AU - Festy, Frederic

AU - Barber, Paul R.

AU - Ameer-Beg, Simon M.

AU - Vojnovic, Borivoj

AU - Gillett, Cheryl

AU - Coolen, Anthony

AU - Kéri, G.

AU - Ellis, Paul A.

AU - Ng, Tony

PY - 2009/9

Y1 - 2009/9

N2 - Genomics and proteomics will improve outcome prediction in cancer and have great potential to help in the discovery of unknown mechanisms of metastasis, ripe for therapeutic exploitation. Current methods of prognosis estimation rely on clinical data, anatomical staging and histopathological features. It is hoped that translational genomic and proteomic research will discriminate more accurately than is possible at present between patients with a good prognosis and those who carry a high risk of recurrence. Rational treatments, targeted to the specific molecular pathways of an individual's high-risk tumor, are at the core of tailored therapy. The aim of targeted oncology is to select the right patient for the right drug at precisely the right point in their cancer journey. Optical proteomics uses advanced optical imaging technologies to quantify the activity states of and associations between signaling proteins by measuring energy transfer between fluorophores attached to specific proteins. Förster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM) assays are suitable for use in cell line models of cancer, fresh human tissues and formalin-fixed paraffin-embedded tissue (FFPE). In animal models, dynamic deep tissue FLIM/FRET imaging of cancer cells in vivo is now also feasible. Analysis of protein expression and post-translational modifications such as phosphorylation and ubiquitination can be performed in cell lines and are remarkably efficiently in cancer tissue samples using tissue microarrays (TMAs). FRET assays can be performed to quantify protein-protein interactions within FFPE tissue, far beyond the spatial resolution conventionally associated with light or confocal laser microscopy. Multivariate optical parameters can be correlated with disease relapse for individual patients. FRET-FLIM assays allow rapid screening of target modifiers using high content drug screens. Specific protein-protein interactions conferring a poor prognosis identified by high content tissue screening will be perturbed with targeted therapeutics. Future targeted drugs will be identified using high content/throughput drug screens that are based on multivariate proteomic assays. Response to therapy at a molecular level can be monitored using these assays while the patient receives treatment: utilizing re-biopsy tumor tissue samples in the neoadjuvant setting or by examining surrogate tissues. These technologies will prove to be both prognostic of risk for individuals when applied to tumor tissue at first diagnosis and predictive of response to specifically selected targeted anticancer drugs. Advanced optical assays have great potential to be translated into real-life benefit for cancer patients.

AB - Genomics and proteomics will improve outcome prediction in cancer and have great potential to help in the discovery of unknown mechanisms of metastasis, ripe for therapeutic exploitation. Current methods of prognosis estimation rely on clinical data, anatomical staging and histopathological features. It is hoped that translational genomic and proteomic research will discriminate more accurately than is possible at present between patients with a good prognosis and those who carry a high risk of recurrence. Rational treatments, targeted to the specific molecular pathways of an individual's high-risk tumor, are at the core of tailored therapy. The aim of targeted oncology is to select the right patient for the right drug at precisely the right point in their cancer journey. Optical proteomics uses advanced optical imaging technologies to quantify the activity states of and associations between signaling proteins by measuring energy transfer between fluorophores attached to specific proteins. Förster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM) assays are suitable for use in cell line models of cancer, fresh human tissues and formalin-fixed paraffin-embedded tissue (FFPE). In animal models, dynamic deep tissue FLIM/FRET imaging of cancer cells in vivo is now also feasible. Analysis of protein expression and post-translational modifications such as phosphorylation and ubiquitination can be performed in cell lines and are remarkably efficiently in cancer tissue samples using tissue microarrays (TMAs). FRET assays can be performed to quantify protein-protein interactions within FFPE tissue, far beyond the spatial resolution conventionally associated with light or confocal laser microscopy. Multivariate optical parameters can be correlated with disease relapse for individual patients. FRET-FLIM assays allow rapid screening of target modifiers using high content drug screens. Specific protein-protein interactions conferring a poor prognosis identified by high content tissue screening will be perturbed with targeted therapeutics. Future targeted drugs will be identified using high content/throughput drug screens that are based on multivariate proteomic assays. Response to therapy at a molecular level can be monitored using these assays while the patient receives treatment: utilizing re-biopsy tumor tissue samples in the neoadjuvant setting or by examining surrogate tissues. These technologies will prove to be both prognostic of risk for individuals when applied to tumor tissue at first diagnosis and predictive of response to specifically selected targeted anticancer drugs. Advanced optical assays have great potential to be translated into real-life benefit for cancer patients.

KW - Biomarker

KW - Breast cancer

KW - FLIM

KW - FRET

KW - Imaging

KW - Molecular diagnostics

KW - Optical proteomics

KW - Personalized medicine

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=72449132469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449132469&partnerID=8YFLogxK

U2 - 10.1007/s11523-009-0116-y

DO - 10.1007/s11523-009-0116-y

M3 - Article

C2 - 19756916

AN - SCOPUS:72449132469

VL - 4

SP - 235

EP - 252

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -